SC 13D/A

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 8)*

 

 

Soleno Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

834203200

(CUSIP Number)

Jeffrey Ferguson

The Carlyle Group

1001 Pennsylvania Avenue, NW

Suite 220 South

Washington, D.C. 20004

(202) 729-5626

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

October 12, 2023

(Date of Event Which Requires Filing of This Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ☐

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

 

 

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 834203200    13D    Page 1 of 15 pages

 

 1    

 Names of Reporting Persons

 

 The Carlyle Group Inc.

 2  

 Check the Appropriate Box if a Member of a Group

 (a) ☐  (b) ☐

 

 3  

 SEC Use Only

 

 4  

 Source of Funds (See Instructions)

 

 OO

 5  

 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

 ☐

 6  

 Citizenship or Place of Organization

 

 Delaware

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

    7    

 Sole Voting Power

 

 0

    8  

 Shared Voting Power

 

 2,893,615

    9  

 Sole Dispositive Power

 

 0

   10  

 Shared Dispositive Power

 

 2,893,615

11    

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 2,893,615

12  

 Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

 ☐

13  

 Percent of Class Represented by Amount in Row (11)

 

 9.99%

14  

 Type of Reporting Person

 

 CO


CUSIP No. 834203200    13D    Page 2 of 15 pages

 

 1    

 Names of Reporting Persons

 

 Carlyle Holdings I GP Inc.

 2  

 Check the Appropriate Box if a Member of a Group

 (a) ☐  (b) ☐

 

 3  

 SEC Use Only

 

 4  

 Source of Funds (See Instructions)

 

 OO

 5  

 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

 ☐

 6  

 Citizenship or Place of Organization

 

 Delaware

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

    7    

 Sole Voting Power

 

 0

    8  

 Shared Voting Power

 

 2,893,615

    9  

 Sole Dispositive Power

 

 0

   10  

 Shared Dispositive Power

 

 2,893,615

11    

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 2,893,615

12  

 Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

 ☐

13  

 Percent of Class Represented by Amount in Row (11)

 

 9.99%

14  

 Type of Reporting Person

 

 CO


CUSIP No. 834203200    13D    Page 3 of 15 pages

 

 1    

 Names of Reporting Persons

 

 Carlyle Holdings I GP Sub L.L.C.

 2  

 Check the Appropriate Box if a Member of a Group

 (a) ☐  (b) ☐

 

 3  

 SEC Use Only

 

 4  

 Source of Funds (See Instructions)

 

 OO

 5  

 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

 ☐

 6  

 Citizenship or Place of Organization

 

 Delaware

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

    7    

 Sole Voting Power

 

 0

    8  

 Shared Voting Power

 

 2,893,615

    9  

 Sole Dispositive Power

 

 0

   10  

 Shared Dispositive Power

 

 2,893,615

11    

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 2,893,615

12  

 Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

 ☐

13  

 Percent of Class Represented by Amount in Row (11)

 

 9.99%

14  

 Type of Reporting Person

 

 OO (Limited Liability Company)


CUSIP No. 834203200    13D    Page 4 of 15 pages

 

 1    

 Names of Reporting Persons

 

 Carlyle Holdings I L.P.

 2  

 Check the Appropriate Box if a Member of a Group

 (a) ☐  (b) ☐

 

 3  

 SEC Use Only

 

 4  

 Source of Funds (See Instructions)

 

 OO

 5  

 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

 ☐

 6  

 Citizenship or Place of Organization

 

 Delaware

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

    7    

 Sole Voting Power

 

 0

    8  

 Shared Voting Power

 

 2,893,615

    9  

 Sole Dispositive Power

 

 0

   10  

 Shared Dispositive Power

 

 2,893,615

11    

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 2,893,615

12  

 Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

 ☐

13  

 Percent of Class Represented by Amount in Row (11)

 

 9.99%

14  

 Type of Reporting Person

 

 PN


CUSIP No. 834203200    13D    Page 5 of 15 pages

 

 1    

 Names of Reporting Persons

 

 CG Subsidiary Holdings L.L.C.

 2  

 Check the Appropriate Box if a Member of a Group

 (a) ☐  (b) ☐

 

 3  

 SEC Use Only

 

 4  

 Source of Funds (See Instructions)

 

 OO

 5  

 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

 ☐

 6  

 Citizenship or Place of Organization

 

 Delaware

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

    7    

 Sole Voting Power

 

 0

    8  

 Shared Voting Power

 

 2,893,615

    9  

 Sole Dispositive Power

 

 0

   10  

 Shared Dispositive Power

 

 2,893,615

11    

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 2,893,615

12  

 Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

 ☐

13  

 Percent of Class Represented by Amount in Row (11)

 

 9.99%

14  

 Type of Reporting Person

 

 OO (Limited Liability Company)


CUSIP No. 834203200    13D    Page 6 of 15 pages

 

 1    

 Names of Reporting Persons

 

 TC Group, L.L.C.

 2  

 Check the Appropriate Box if a Member of a Group

 (a) ☐  (b) ☐

 

 3  

 SEC Use Only

 

 4  

 Source of Funds (See Instructions)

 

 OO

 5  

 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

 ☐

 6  

 Citizenship or Place of Organization

 

 Delaware

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

    7    

 Sole Voting Power

 

 0

    8  

 Shared Voting Power

 

 2,893,615

    9  

 Sole Dispositive Power

 

 0

   10  

 Shared Dispositive Power

 

 2,893,615

11    

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 2,893,615

12  

 Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

 ☐

13  

 Percent of Class Represented by Amount in Row (11)

 

 9.99%

14  

 Type of Reporting Person

 

 OO (Limited Liability Company)


CUSIP No. 834203200    13D    Page 7 of 15 pages

 

 1    

 Names of Reporting Persons

 

 Carlyle Investment Management L.L.C.

 2  

 Check the Appropriate Box if a Member of a Group

 (a) ☐  (b) ☐

 

 3  

 SEC Use Only

 

 4  

 Source of Funds (See Instructions)

 

 OO

 5  

 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

 ☐

 6  

 Citizenship or Place of Organization

 

 Delaware

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

    7    

 Sole Voting Power

 

 0

    8  

 Shared Voting Power

 

 2,893,615

    9  

 Sole Dispositive Power

 

 0

   10  

 Shared Dispositive Power

 

 2,893,615

11    

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 2,893,615

12  

 Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

 ☐

13  

 Percent of Class Represented by Amount in Row (11)

 

 9.99%

14  

 Type of Reporting Person

 

 OO (Limited Liability Company)


CUSIP No. 834203200    13D    Page 8 of 15 pages

 

 1    

 Names of Reporting Persons

 

 Carlyle Genesis UK LLC

 2  

 Check the Appropriate Box if a Member of a Group

 (a) ☐  (b) ☐

 

 3  

 SEC Use Only

 

 4  

 Source of Funds (See Instructions)

 

 OO

 5  

 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

 ☐

 6  

 Citizenship or Place of Organization

 

 Delaware

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

    7    

 Sole Voting Power

 

 0

    8  

 Shared Voting Power

 

 2,893,615

    9  

 Sole Dispositive Power

 

 0

   10  

 Shared Dispositive Power

 

 2,893,615

11    

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 2,893,615

12  

 Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

 ☐

13  

 Percent of Class Represented by Amount in Row (11)

 

 9.99%

14  

 Type of Reporting Person

 

 OO (Limited Liability Company)


CUSIP No. 834203200    13D    Page 9 of 15 pages

 

 1    

 Names of Reporting Persons

 

 Abingworth LLP

 2  

 Check the Appropriate Box if a Member of a Group

 (a) ☐  (b) ☐

 

 3  

 SEC Use Only

 

 4  

 Source of Funds (See Instructions)

 

 OO

 5  

 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

 ☐

 6  

 Citizenship or Place of Organization

 

 England and Wales

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

    7    

 Sole Voting Power

 

 0

    8  

 Shared Voting Power

 

 2,893,615

    9  

 Sole Dispositive Power

 

 0

   10  

 Shared Dispositive Power

 

 2,893,615

11    

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 2,893,615

12  

 Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

 ☐

13  

 Percent of Class Represented by Amount in Row (11)

 

 9.99%

14  

 Type of Reporting Person

 

 PN


CUSIP No. 834203200    13D    Page 10 of 15 pages

 

 1    

 Names of Reporting Persons

 

 Abingworth Bioventures VII LP

 2  

 Check the Appropriate Box if a Member of a Group

 (a) ☐  (b) ☐

 

 3  

 SEC Use Only

 

 4  

 Source of Funds (See Instructions)

 

 OO

 5  

 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

 ☐

 6  

 Citizenship or Place of Organization

 

 England and Wales

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

    7    

 Sole Voting Power

 

 0

    8  

 Shared Voting Power

 

 2,893,615

    9  

 Sole Dispositive Power

 

 0

   10  

 Shared Dispositive Power

 

 2,893,615

11    

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 2,893,615

12  

 Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

 ☐

13  

 Percent of Class Represented by Amount in Row (11)

 

 9.99%

14  

 Type of Reporting Person

 

 PN


CUSIP No. 834203200    13D    Page 11 of 15 pages

 

Explanatory Note

This Amendment No. 8 to Schedule 13D (“Amendment No. 8”) amends and supplements the Schedule 13D originally filed with the United States Securities and Exchange Commission on December 27, 2018 (as amended to date, the “Schedule 13D”), relating to the shares of common stock, par value $0.001 per share (the “Common Stock”), of Soleno Therapeutics, Inc., a Delaware corporation (the “Issuer”). Capitalized terms used herein without definition shall have the meanings set forth in the Schedule 13D.

 

Item 3.

Source and Amount of Funds or Other Consideration.

Item 3 of the Schedule 13D is hereby amended and supplemented as follows:

On October 12, 2023, Abingworth Bioventures VII LP exercised its right to purchase 1,778,000 shares of Common Stock for $2.50 per share pursuant to the terms of the Tranche B Warrants. Pursuant to the terms of the Tranche B Warrants, which prevents the Tranche B Warrants from being exercised for shares of Common Stock if such exercise would result in Abingworth Bioventures VII LP becoming the beneficial owner of more than 9.99% of the Issuer’s voting securities, Abingworth Bioventures VII LP was issued 1,326,368 shares of Common Stock and 451,632 prefunded warrants to purchase shares of Common Stock (the “Prefunded Warrants”).

The Prefunded Warrants are immediately exercisable for $0.01 per share and do not expire. However, the Prefunded Warrants contain provisions preventing the Prefunded Warrants from being exercised if such exercise would result in Abingworth Bioventures VII LP becoming the beneficial owner of more than 9.99% of the Issuer’s voting securities.

Abingworth Bioventures VII LP used investment capital to fund the exercise of the Tranche B Warrants.


CUSIP No. 834203200    13D    Page 12 of 15 pages

 

Item 5.

Interest in Securities of the Issuer.

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

(a) – (b) The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 28,965,118 shares of Common Stock, which includes (i) 27,602,939 shares of Common Stock outstanding as of October 12, 2023, as provided by the Issuer, (ii) 1,326,368 shares of Common Stock issued to Abingworth Bioventures VII LP pursuant to the Tranche B Warrant exercise, (iii) 20,247 shares of Common Stock underlying stock options exercisable within 60 days as of the date hereof and (iv) 15,564 shares of Common Stock underlying warrants convertible within 60 days as of the date hereof.

 

Reporting Person

   Amount
beneficially
owned
     Percent
of class
    Sole
power to
vote or to
direct the
vote
     Shared
power to
vote or to
direct the
vote
     Sole power
to dispose
or to direct
the
disposition
     Shared
power to
dispose or to
direct the
disposition
 

The Carlyle Group Inc.

     2,893,615        9.99     0        2,893,615        0        2,893,615  

Carlyle Holdings I GP Inc.

     2,893,615        9.99     0        2,893,615        0        2,893,615  

Carlyle Holdings I GP Sub L.L.C.

     2,893,615        9.99     0        2,893,615        0        2,893,615  

Carlyle Holdings I L.P.

     2,893,615        9.99     0        2,893,615        0        2,893,615  

CG Subsidiary Holdings L.L.C.

     2,893,615        9.99     0        2,893,615        0        2,893,615  

TC Group, L.L.C.

     2,893,615        9.99     0        2,893,615        0        2,893,615  

Carlyle Investment Management L.L.C.

     2,893,615        9.99     0        2,893,615        0        2,893,615  

Carlyle Genesis UK LLC

     2,893,615        9.99     0        2,893,615        0        2,893,615  

Abingworth LLP

     2,893,615        9.99     0        2,893,615        0        2,893,615  

Abingworth Bioventures VII LP

     2,893,615        9.99     0        2,893,615        0        2,893,615  

Includes (i) 2,857,804 shares of Common Stock held of record by Abingworth Bioventures VII LP, (ii) 20,247 shares of Common Stock underlying stock options exercisable within 60 days as of the date hereof and (iii) 15,564 shares of Common Stock underlying warrants convertible within 60 days as of the date hereof.

The amount of securities disclosed excludes (i) 514,666 shares of Common Stock underlying the March 2022 Warrants, which contain a provision prohibiting exercise to the extent that the holder, together with its affiliates, would beneficially own in excess of 4.99% of the total number of shares of Common Stock then issued and outstanding, and (ii) 1,213,758 shares of Common Stock underlying the Prefunded Warrants, which contain a provision prohibiting exercise to the extent that the holder, together with its affiliates, would beneficially own in excess of 9.99% of the total number of shares of Common Stock then issued and outstanding.


CUSIP No. 834203200    13D    Page 13 of 15 pages

 

The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Abingworth Bioventures VII LP has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by Abingworth Bioventures VII LP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by Abingworth Bioventures VII LP, but each disclaims beneficial ownership of such securities.

 

(c)

Other than as described in Item 3 above, during the past 60 days, the Reporting Persons have not effected any transactions with respect to the Common Stock.

 

(d)

None.

 

(e)

Not applicable.


CUSIP No. 834203200    13D    Page 14 of 15 pages

 

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: October 16, 2023

 

The Carlyle Group Inc.
By:  

/s/ Anne Frederick, attorney-in-fact

Name:   John C. Redett
Title:   Chief Financial Officer
Carlyle Holdings I GP Inc.
By:  

/s/ Anne Frederick, attorney-in-fact

Name:   John C. Redett
Title:   Managing Director and Chief Financial Officer
Carlyle Holdings I GP Sub L.L.C.
By: Carlyle Holdings I GP Inc., its sole member
By:  

/s/ Anne Frederick, attorney-in-fact

Name:   John C. Redett
Title:   Managing Director and Chief Financial Officer
Carlyle Holdings I L.P.
By:  

/s/ Anne Frederick, attorney-in-fact

Name:   John C. Redett
Title:   Managing Director
CG Subsidiary Holdings L.L.C.
By:  

/s/ Anne Frederick, attorney-in-fact

Name:   John C. Redett
Title:   Managing Director
TC Group, L.L.C.
By:  

/s/ Anne Frederick, attorney-in-fact

Name:   John C. Redett
Title:   Managing Director


CUSIP No. 834203200    13D    Page 15 of 15 pages

 

Carlyle Investment Management L.L.C.
By:  

/s/ Anne Frederick, attorney-in-fact

Name:   John C. Redett
Title:   Chief Financial Officer
Carlyle Genesis UK LLC
By: Carlyle Investment Management L.L.C., its sole member
By:  

/s/ Anne Frederick, attorney-in-fact

Name:   John C. Redett
Title:   Chief Financial Officer
Abingworth LLP
By:  

/s/ John Heard

Name:   John Heard
Title:   Authorized Signatory
Abingworth Bioventures VII LP
By:  

/s/ John Heard

Name:   John Heard
Title:   Authorized Signatory